Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses

By sjmartinez • November 16, 2022

Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F, Sieg SF, Ritz J, Moser CB, Eron JJ, Currier JS, Klekotka P, Sette A, Wohl DA, Daar ES, Hughes MD, Chew KW, Smith DM, Crotty S. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. JCI Insight. 2022 Nov 15:e163471. doi: 10.1172/jci.insight.163471. Epub ahead of print. PMID: 36378539.

Tags: Adaptive immunity, covid-19, Immunology, Infectious Diseases, Publications

A Tale of Two Islands – Leptospirosis in Strikingly Different Ecological Settings Reveals Pathogenomic Insights

Haake DA. A Tale of Two Islands - Leptospirosis in Strikingly Different Ecological Settings Reveals Pathogenomic Insights. Am J Trop Med Hyg. 2024 May 2:tpmd240254.[...]

Contribution of syphilis to adverse pregnancy outcomes in people living with and without HIV in south Brazil: 2008-2018

Yang LZ, Sundar KG, Cambou MC, Swayze EJ, Segura ER, Gonçalves de Melo M, Santos BR, Rosângela Dos Santos Varella I, Nielsen-Saines K. Contribution of[...]

Editorial: Improving the delivery of pre-exposure prophylaxis (PrEP) to eliminate vertical HIV transmission

Njuguna I, Saidi F, Joseph Davey D, Chi BH, Pintye J. Editorial: Improving the delivery of pre-exposure prophylaxis (PrEP) to eliminate vertical HIV transmission. Front[...]